Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design

Copyright © 2018. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 195(2018) vom: 05. Okt., Seite 28-35
1. Verfasser: Jackson, Doreen O (VerfasserIn)
Weitere Verfasser: Trappey, Francois A, Clifton, G Travis, Vreeland, Timothy J, Peace, Kaitlin M, Hale, Diane F, Litton, Jennifer K, Murray, James L, Perez, Sonia A, Papamichail, Michael, Mittendorf, Elizabeth A, Peoples, George E
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Randomized Controlled Trial Breast Cancer HER2 expression HLA-status Immunotherapy Cancer Vaccines HLA-A2 Antigen Vaccines, Subunit mehr... Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1 ERBB2 protein, human EC 2.7.10.1 Receptor, ErbB-2
Beschreibung
Zusammenfassung:Copyright © 2018. Published by Elsevier Inc.
Immunotherapy, using peptide-based cancer vaccines is being studied to assess its potential in breast cancer. Trials of HLA-restricted peptide vaccines have been difficult to enroll given HLA subtype restrictions. It is necessary to determine the prognostic significance of HLA-status in breast cancer if patients who are ineligible to receive a vaccine due to their HLA-status are used as controls. The impact of targeted tumor associated antigen expression, when it effects eligibility is also important. We examined control patients from two randomized phase II trials that tested HER2-peptide vaccines to determine the effect of HLA-A2 status and HER2 expression on disease-free survival. The analysis showed that HLA-A2-status does not affect disease-free survival, regardless of HER2 expression suggesting that HLA-A2 negative patients can be used as control patients. Additionally, HER2 over-expression was associated with a better disease-free survival in this population, underscoring the need for additional therapies in HER2 low-expressing breast cancer. ClinicalTrials.gov Identifier: NCT00524277
Beschreibung:Date Completed 27.08.2019
Date Revised 27.08.2019
published: Print-Electronic
ClinicalTrials.gov: NCT00524277
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.06.008